Daiichi Sankyo Co., Ltd.

Phone: +81 3-6225-1111

Web:https://www.daiichisankyo.com

Native name 第一三共株式会社
Romanized name Daiichi Sankyō kabushiki gaisha
Type Public KK
Traded as TYO: 4568
TOPIX Large 70 Component
TOPIX 100 Component
Nikkei 225 Component
Industry Pharmaceutical
Predecessors
  • Daiichi Pharmaceutical Company
  • Sankyo Company
Founded Tokyo, Japan (2005) (by merger)
Headquarters Daiichi Sankyo Building A/B 3-5-1, Nihonbashi-honcho, Chūō-ku, Tokyo 103-8426, Japan
Key people
  • Sunao Manabe (Representative Director, and President)
  • Ken Keller (President and CEO, Daiichi Sankyo, Inc.)
Products
  • Medical equipment
  • Pharmaceutical products
  • Veterinary medicines
Revenue Increase $ 9.028 billion USD (FY 2019) (¥ 981.8 billion JPY) (FY 2019)
Net income Increase $ 1.276 billion USD (FY 2019) (¥ 138.8 billion JPY) (FY 2019)
Number of employees 15,348 (as of March 2020)
Website http://www.daiichisankyo.com

Daiichi Sankyo Company, Limited (Japanese: 第一三共株式会社, Hepburn: Daiichi Sankyō Kabushiki-gaisha) is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.

Daiichi Sankyo, Inc. (DSI) began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development (Daiichi Sankyo Pharma Development), is headquartered in Basking Ridge, New Jersey.

Daiichi Sankyo Europe, GmbH (DSE), the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.

Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

For detailed contact information visit location pages below.

Daiichi Sankyo Co., Ltd.'s locations around the world

North AmericaExpand
South AmericaExpand

Clinical Trials sponsored by Daiichi Sankyo Co., Ltd.

3
Prenumerera